A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma

Blood Cancer J. 2019 Jul 31;9(8):58. doi: 10.1038/s41408-019-0217-5.

Authors

Andrew Spencer¹, Patricia Walker², Parisa Asvadi³, Douglas H Campbell⁴, Kate Reed², Ben R Herbert⁵, Edmond J Breen⁶, Michael C Copeman⁷, Rosanne D Dunn⁸

Affiliations

¹ Alfred Health-Monash University, Melbourne, VIC, Australia. [email protected].
² Alfred Health-Monash University, Melbourne, VIC, Australia.
³ Aurobindo Pharma Ltd, Hyderabad, AP, India.
⁴ Minomic International Ltd, Sydney, NSW, Australia.
⁵ Kolling Institute, Northern Sydney Local Health District, Sydney Medical School Northern, University of Sydney, St Leonards, NSW, Australia.
⁶ Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW, Australia.
⁷ 45 Baringa Road, Northbridge, NSW, Australia.
⁸ HaemaLogiX Pty Ltd, Sydney, NSW, Australia.

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / pharmacokinetics
Antineoplastic Agents, Immunological / administration & dosage*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / pharmacokinetics
Dose-Response Relationship, Drug
Humans
Immunoglobulin kappa-Chains / immunology*
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Multiple Myeloma / microbiology
Multiple Myeloma / pathology
Prognosis
Tissue Distribution

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulin kappa-Chains
MDX-1097